C12N 2800/103
For invertebrates
Official title: for invertebrates
C12N2800/103 (For invertebrates) appears on 31 US grants and 56 published applications in this corpus.
Search patents in C12N- Granted patents
- 31
- Published applications
- 56
- Assignees
- 37
- Inventors
- 117
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 0 | 3 |
| 2012 | 2 | 1 |
| 2013 | 1 | 2 |
| 2014 | 2 | 4 |
| 2015 | 3 | 3 |
| 2016 | 2 | 3 |
| 2017 | 1 | 3 |
| 2018 | 6 | 3 |
| 2019 | 2 | 4 |
| 2020 | 2 | 1 |
| 2021 | 1 | 4 |
| 2022 | 1 | 4 |
| 2023 | 1 | 2 |
| 2024 | 2 | 7 |
| 2025 | 3 | 2 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for insect control4 Aug 2026US 12,698,310 B2Indiana University Research and Technology Corporation
- Bacillus thuringiensis toxin receptors and uses thereof17 Mar 2026US 12,577,284 B2Monsanto Technology LLC
- Silk gland recombinant expression vector of silkworm (Bombyx mori) expressing human epidermal growth factor, preparation method and use thereof30 Dec 2025US 12,509,712 B2Southwest University
- Expression cassette for expressing gene comprising overlapping open reading frames in insect cell and application thereof18 Nov 2025US 12,473,571 B2Genveoyager (Wuhan) Co., Ltd.
- Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors14 Oct 2025US 12,442,015 B2Generation Bio Co.
- Bacillus thuringiensis toxin receptors and uses thereof30 Jul 2026US 2026/0217787 A1Monsanto Technology LLC
- Mitigation of persistent harmful compounds12 Mar 2026US 2026/0070103 A1
- Silk Gland Recombinant Expression Vector of Silkworm (Bombyx Mori) Expressing Human Epidermal Growth Factor, Preparation Method and Use Thereof2 Oct 2025US 2025/0305020 A1Southwest University
- Genome-modified silkworm producing chimeric silk thread10 Jul 2025US 2025/0223602 A1Kowa Company, Ltd.
- Human papillomavirus type 18 chimeric protein and use thereof26 Sep 2024US 2024/0317808 A1Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Most cited
By later US patents
- Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV45US 8,512,981 B2Amsterdam Molecular Therapeutics B.V. · 2013
- Optimization of expression of parvoviral rep and cap proteins in insect cells38US 8,642,314 B2Amsterdam Molecular Therapeutics (AMT) B.V. · 2014
- Optimization of expression of parvoviral rep and cap proteins in insect cells34US 9,260,724 B2uniQure IP B.V. · 2016
- Mutated rep encoding sequences for use in AAV production31US 9,228,174 B2uniQure IP B.V. · 2016
- Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV18US 9,708,627 B2uniQure IP B.V. · 2017